News AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Real-time Estimate Cboe BZX Other stock markets 02:24:01 2024-05-23 pm EDT			5-day change	1st Jan Change
6.105 ^USD	-3.40%		-4.67%	-21.94%

May. 21	AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System	MT
May. 06	AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System	May. 21	MT
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System	May. 21	BU
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions	May. 06	BU
AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)	May. 06	CI
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results, Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture	Apr. 05	AQ
AngioDynamics Receives 510(k) Clearance for AlphaVac F18 System in Treatment of PE	Apr. 05	AQ
Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target	Apr. 05	MT
AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device	Apr. 04	MT
AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System	Apr. 04	DJ
Transcript : AngioDynamics, Inc., Q3 2024 Earnings Call, Apr 04, 2024	Apr. 04
AngioDynamics Gets FDA Clearance For Pulmonary Embolism Treatment	Apr. 04	DJ
AngioDynamics: Fiscal Q3 Earnings Snapshot	Apr. 04	AQ
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q3 Revenue $66M	Apr. 04	MT
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture	Apr. 04	BU
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 04	CI
AngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024	Apr. 04	CI
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024	Apr. 04	CI
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE	Apr. 04	BU
AngioDynamics, Inc. Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE	Apr. 04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Summary

Filters